Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer

The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first (177)Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant...

Descripción completa

Detalles Bibliográficos
Autores principales: Gudenkauf, Lisa M., Chavez, Melody N., Maconi, Melinda Leigh, Geiss, Carley, Seyedroudbari, Ameen, Thin, Pan, Hoogland, Aasha I., Nguyen, Kathleen, Murthy, Vishnu, Armstrong, Wesley R., Komrokji, Khaled, Oswald, Laura B., Jim, Heather S.L., El-Haddad, Ghassan, Fendler, Wolfgang P., Herrmann, Ken, Cella, David, Czernin, Johannes, Hofman, Michael S., Dicker, Adam P., Calais, Jeremie, Tagawa, Scott T., Gonzalez, Brian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Featured Clinical Investigation Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241017/
https://www.ncbi.nlm.nih.gov/pubmed/36635088
http://dx.doi.org/10.2967/jnumed.122.264946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241017/
https://www.ncbi.nlm.nih.gov/pubmed/36635088
http://dx.doi.org/10.2967/jnumed.122.264946

Ejemplares similares